kura
oncology
participate
three
upcoming
investor
conferences
san
diego
globe
newswire
kura
oncology
nasdaq
kura
biopharmaceutical
company
committed
realizing
promise
precision
medicines
treatment
cancer
today
announced
management
scheduled
participate
three
upcoming
virtual
investor
conferences
presentation
troy
wilson
president
chief
executive
officer
credit
suisse
th
annual
healthcare
conference
november
et
pt
annual
healthcare
conference
november
et
pt
presentation
marc
grasso
chief
financial
officer
chief
business
officer
stifel
virtual
healthcare
conference
november
et
pt
fireside
chat
wilson
piper
sandler
annual
healthcare
conference
fireside
chat
available
company
ir
website
beginning
week
november
virtual
conference
held
december
live
audio
webcasts
credit
suisse
stifel
presentations
available
investors
section
kura
website
archived
replays
available
days
following
three
events
kura
oncology
kura
oncology
biopharmaceutical
company
committed
realizing
promise
precision
medicines
treatment
cancer
company
pipeline
consists
two
wholly
owned
small
molecule
drug
candidates
target
cancer
signaling
pathways
strong
scientific
clinical
rationale
improve
outcomes
identifying
patients
likely
benefit
treatment
kura
advanced
drug
candidate
tipifarnib
potent
selective
orally
bioavailable
farnesyl
transferase
inhibitor
currently
trial
patients
recurrent
metastatic
hras
mutant
head
neck
squamous
cell
carcinoma
company
pipeline
also
highlighted
potent
selective
menin
inhibitor
currently
phase
clinical
trial
patients
relapsed
refractory
acute
myeloid
leukemia
additional
information
kura
please
visit
company
website
contacts
company
pete
de
spain
vice
president
investor
relations
corporate
communications
pete
investors
robert
uhl
managing
director
westwicke
icr
media
jason
spark
managing
director
canale
communications
jason
